General Announcement::Press Release

Issuer & Securities

Issuer/ Manager
BIOCON BIOLOGICS GLOBAL PLC
Securities
BIOCONBIO US$800M6.67%N291009A - US090978AA56 - RJUB
BIOCONBIO US$800M6.67%N291009R - USG11185AA61 - KSEB
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
23-Dec-2025 12:59:26
Status
New
Announcement Sub Title
Press Release
Announcement Reference
SG251223OTHRZK56
Submitted By (Co./ Ind. Name)
Biocon Biologics Limited / Akhilesh Nand
Designation
Company Secretary
Effective Date and Time of the event
23/12/2025 10:00:00
Description (Please provide a detailed description of the event in the box below)
Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement

Attachments

BBL_FKB_HULIO_SGX_23122025.pdf
Total size =247K